Department of Pharmacology and Physiology, Georgetown University Medical Center, 3900 Reservoir Road, NW, Washington D.C. 20057, USA.
Pharmacol Res. 2020 Jun;156:104832. doi: 10.1016/j.phrs.2020.104832. Epub 2020 Apr 15.
Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients.
血管紧张素受体阻滞剂 (ARBs) 除了具有降压作用外，还具有多种重要的保护作用，包括减轻炎症。ARBs 可直接保护肺部免受病毒感染引起的严重急性呼吸综合征，包括冠状病毒。ARB 给药可增强 ACE2 的保护作用。基于这些原因，患有高血压、糖尿病和肾脏疾病的患者（目前 COVID-19 大流行的合并症）必须继续接受 ARB 治疗。应进行对照临床研究，以确定 ARBs 是否可作为 COVID-19 患者的附加治疗方法。
